Most squamous cell carcinomas of the skin are not deadly. The vast majority are caught early, treated with a straightforward procedure, and never come back. But squamous cell carcinoma isn’t one disease. It can appear on the skin, in the lungs, in the head and neck, and in other organs, and the prognosis varies enormously depending on where it starts and how far it has spread.
Skin Squamous Cell Carcinoma: The Common Case
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer, and the numbers tell a reassuring story for most people. At the earliest stage (T1), only about 1.5% of tumors spread to nearby lymph nodes. The American Cancer Society estimates that between 2,000 and 8,000 people die from basal and squamous cell skin cancers combined each year in the U.S., with the majority of those deaths attributed to squamous cell. That sounds significant until you consider that roughly 1.8 million cases of cSCC are diagnosed annually. For any individual patient caught at an early stage, the odds are overwhelmingly in their favor.
Treatment for early-stage skin SCC is typically a same-day surgical procedure, often Mohs surgery, which removes thin layers of tissue until no cancer cells remain. Cure rates for these early tumors exceed 95%.
When Skin SCC Becomes Dangerous
The picture changes substantially with higher-stage tumors. As the cancer grows deeper into the skin or develops certain high-risk features, the chance of spreading rises sharply:
- Stage T1: about 1.5% spread to lymph nodes
- Stage T2: about 9.8%
- Stage T3: about 19.6%
- Stage T4: about 47.4%
The features that push a tumor into higher stages include large size (generally over 2 cm), growth deep into the tissue beneath the skin, location on the ear or lip, poorly organized cancer cells under the microscope, and invasion into nerves. A tumor with several of these features is far more likely to recur after surgery or spread to lymph nodes and distant organs.
Once SCC has spread beyond the skin, it becomes much harder to treat and can be fatal. Tumors that reach distant organs carry a poor prognosis, similar to advanced cancers elsewhere in the body.
Organ Transplant Recipients Face Higher Risk
People with suppressed immune systems, particularly organ transplant recipients, face a dramatically different risk profile. A 10-year study of over 6,200 heart transplant patients found that the incidence of cutaneous SCC increased 4 to 30 times compared to the general population of the same age and sex. These cancers also tend to behave more aggressively, growing faster and spreading more readily. For transplant recipients, regular skin checks aren’t optional. They’re essential for catching tumors before they reach a dangerous stage.
SCC in the Lungs: A Different Disease
Squamous cell carcinoma of the lung is a fundamentally different situation. It falls under the umbrella of non-small cell lung cancer and carries a much grimmer prognosis than the skin version. The overall five-year survival rate for lung and bronchus cancers is 29.5%. When the cancer is still confined to the lung, survival is about 65.5%, but over half of lung cancers are already at a distant stage when diagnosed, where five-year survival drops to just 10.5%.
The reason lung SCC is so much deadlier comes down to detection. Skin cancers are visible. You can see them, your partner can notice them, your doctor can spot them during a routine exam. Lung cancers grow silently for months or years, often producing no symptoms until they’ve already spread. By the time someone develops a persistent cough, unexplained weight loss, or chest pain, the cancer may have moved well beyond the lungs.
SCC in the Head and Neck
Squamous cell carcinoma also develops in the throat, mouth, tongue, and voice box. These cancers are often linked to tobacco use, heavy alcohol consumption, or infection with human papillomavirus (HPV). Prognosis depends heavily on the exact location and whether the cancer has spread to neck lymph nodes. A lump in the neck or persistent throat pain that doesn’t resolve can be an early sign. HPV-positive head and neck cancers tend to respond better to treatment and carry a more favorable outlook than HPV-negative ones.
Immunotherapy for Advanced Cases
For people whose skin SCC has grown too large for surgery or has spread, newer treatments have changed the outlook. Immunotherapy drugs that help the immune system recognize and attack cancer cells have shown strong results. In clinical trials, about 46% of patients with advanced cutaneous SCC responded to immunotherapy, with tumors shrinking or stabilizing. In a more recent trial using higher doses, the response rate reached 62%, and 22% of patients saw their tumors disappear completely. At one year, 73% of patients in that trial were still alive.
These numbers represent a genuine shift. Before immunotherapy became available, options for advanced skin SCC were limited and outcomes were poor. While these treatments don’t work for everyone and can cause significant immune-related side effects, they’ve given people with advanced disease a realistic chance at long-term control.
Signs a Skin SCC Needs Urgent Attention
Most skin SCCs appear as firm, red bumps, flat sores with a scaly crust, or new sores on top of old scars. The warning signs that a tumor may be higher risk include rapid growth over weeks rather than months, a sore that bleeds repeatedly and won’t heal, a lesion larger than a coin, or a growth in a previously treated area. Any new lump in the neck near a known skin cancer is a red flag for spread to lymph nodes and warrants prompt evaluation.
Pain, numbness, or tingling around a skin lesion can indicate the cancer has invaded nearby nerves, which is one of the features associated with higher metastasis rates. Tumors on the ears, lips, and temples also carry elevated risk compared to those on the trunk or limbs.